Table 5. Type of treatment drugs in CC-P individuals

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Male, n=164** | **Female, n=279** | **All, n=443** |
| **Osmotic Laxatives** | 106 (64.6%) | 176 (63.1%) | 282 (63.7%) |
| **Stimulant Laxatives** | 62 (37.8%) | 92 (33.0%) | 154 (34.8%) |
| **Lubiprostone** | 9 (5.5%) | 9 (3.2%) | 18 (4.1%) |
| **Linaclotide** | 3 (1.8%) | 5 (1.8%) | 8 (1.8%) |
| **Elobixibat** | 1 (0.6%) | 4 (1.4%) | 5 (1.1%) |
| **Enema/Suppositories** | 9 (5.5%) | 11 (3.9%) | 20 (4.5%) |
| **Kampo medicine** | 22 (13.4%) | 45 (16.1%) | 67 (15.1%) |
| **Mosapride** | 6 (3.7%) | 9 (3.2%) | 15 (3.4%) |
| **Other drugs** | 15 (9.1%) | 20 (7.2%) | 35 (7.9%) |